Objective:
Emphasize the significance of the Orphan Drug Act in the context of rare diseases.
Key Findings:
- Add a finding about the necessity of clinician education to combat underdiagnosis.
Interpretation:
Strengthen the urgency of addressing barriers to treatment.
Limitations:
- Include the impact of high drug costs on patient access.
Conclusion:
Stress the importance of collaboration among stakeholders to enhance patient outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
